Want to see ABCL full AI Analyst Report?
Compare AbCellera Biologics (ABCL) vs. Competitors
Comparison Results
| Name | Price | Market Cap | P/E Ratio | Yearly Gain | Analyst Consensus | Analyst Price Target | Compare | Top Analysts' Price Target | Smart Score | Follow |
|---|---|---|---|---|---|---|---|---|---|---|
| ABCLAbCellera Biologics | $12.27 | $3.98B | -22.72 | 128.92% | Strong Buy | ABCL | ||||
| XNCRXencor | $29.82 | $2.22B | -13.74 | 111.04% | Strong Buy | ABCL vs XNCR | ||||
| ZYMEZymeworks | $28.61 | $2.03B | -14.16 | 49.63% | Strong Buy | ABCL vs ZYME | ||||
| RXRXRecursion Pharmaceuticals | $4.03 | $2.41B | -3.88 | -28.67% | Moderate Buy | ABCL vs RXRX | ||||
| ABSIAbSci | $11.13 | $1.91B | -13.91 | 172.13% | Strong Buy | ABCL vs ABSI | ||||
| GENBGenerate Biomedicines, Inc. | $14.46 | $1.86B | -8.56 | 14.31% | Strong Buy | ABCL vs GENB |
Performance Comparison
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ABCL | AbCellera Biologics | 12.27 | 6.90 | 128.49% | |
| XNCR | Xencor | 29.82 | 15.88 | 113.92% | |
| ZYME | Zymeworks | 28.61 | 9.72 | 51.46% | |
| RXRX | Recursion Pharmaceuticals | 4.03 | -1.41 | -25.92% | |
| ABSI | AbSci | 11.13 | 7.02 | 170.80% | |
| GENB | Generate Biomedicines, Inc. | 14.46 | 1.81 | 14.31% |
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts